JP2023519959A5 - - Google Patents

Info

Publication number
JP2023519959A5
JP2023519959A5 JP2022559484A JP2022559484A JP2023519959A5 JP 2023519959 A5 JP2023519959 A5 JP 2023519959A5 JP 2022559484 A JP2022559484 A JP 2022559484A JP 2022559484 A JP2022559484 A JP 2022559484A JP 2023519959 A5 JP2023519959 A5 JP 2023519959A5
Authority
JP
Japan
Prior art keywords
approximately
transdermal patch
weight
dextromethorphan
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519959A (ja
JP7798361B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024572 external-priority patent/WO2021202329A1/en
Publication of JP2023519959A publication Critical patent/JP2023519959A/ja
Publication of JP2023519959A5 publication Critical patent/JP2023519959A5/ja
Application granted granted Critical
Publication of JP7798361B2 publication Critical patent/JP7798361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559484A 2020-03-30 2021-03-29 デキストロメトルファンの経皮送達 Active JP7798361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001607P 2020-03-30 2020-03-30
US63/001,607 2020-03-30
PCT/US2021/024572 WO2021202329A1 (en) 2020-03-30 2021-03-29 Transdermal delivery of dextromethorphan

Publications (3)

Publication Number Publication Date
JP2023519959A JP2023519959A (ja) 2023-05-15
JP2023519959A5 true JP2023519959A5 (cg-RX-API-DMAC7.html) 2024-04-03
JP7798361B2 JP7798361B2 (ja) 2026-01-14

Family

ID=77928529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559484A Active JP7798361B2 (ja) 2020-03-30 2021-03-29 デキストロメトルファンの経皮送達

Country Status (10)

Country Link
US (1) US20240216358A1 (cg-RX-API-DMAC7.html)
EP (1) EP4125902A4 (cg-RX-API-DMAC7.html)
JP (1) JP7798361B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161416A (cg-RX-API-DMAC7.html)
CN (1) CN115996709A (cg-RX-API-DMAC7.html)
AU (1) AU2021249031A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173322A1 (cg-RX-API-DMAC7.html)
IL (1) IL296624A (cg-RX-API-DMAC7.html)
TW (1) TW202203921A (cg-RX-API-DMAC7.html)
WO (1) WO2021202329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
CN122440635A (zh) 2020-12-01 2026-07-24 安泰赛普生物风投二代有限责任公司 用于降低抑郁症患者的自杀风险的安非他酮和右美沙芬
IT202100029225A1 (it) * 2021-11-18 2023-05-18 Capietal Italia S R L Miscela comprendente un cannabidiolo CBD, un beta-cariofillene BCP e un furanodiene, per uso in un metodo di trattamento del dolore neuropatico periferico
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
WO2024077133A1 (en) * 2022-10-06 2024-04-11 Shinkei Therapeutics, Inc. Transdermal delivery of dextromethorphan
KR20250114110A (ko) 2022-11-28 2025-07-28 안테씨프 바이오벤쳐스 투 엘엘씨 약물 활성의 조절제로서의 부프로피온
CN119700641A (zh) * 2025-02-26 2025-03-28 深圳市药欣生物科技有限公司 舌下施用的右美沙芬药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194281T1 (de) * 1994-09-14 2000-07-15 Minnesota Mining & Mfg Matrix für transdermale wirkstofffreisetzung
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CA2289190A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
CA2729346A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
CA2815898C (en) * 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US12144899B2 (en) * 2018-04-25 2024-11-19 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device

Similar Documents

Publication Publication Date Title
JP6845162B2 (ja) ケタミン経皮送達システム
JP7798361B2 (ja) デキストロメトルファンの経皮送達
RU2408368C2 (ru) Препараты соли бупропиона с модифицированным высвобождением
JP2022060428A (ja) 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
US20200030251A1 (en) Transdermal drug delivery system for ketamine
RU2007122410A (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту
US8017146B2 (en) Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised
JP2022087276A (ja) メマンチン経皮送達システム
JP2002510600A (ja) メチルフェニデートで注意欠乏障害及び注意欠乏/活動亢進障害を治療する組成物及び方法
JP2003531157A (ja) オキシブチニン治療に関連した有害な経験の最小化
JP2020536953A5 (cg-RX-API-DMAC7.html)
US20120171297A1 (en) Threo-dops controlled release formulation
US9408802B1 (en) Seven day drug in adhesive transdermal delivery
CA2598406C (en) Method for a treatment with a medicament combination and medicament combinations suitable for the same
EP3522843B1 (en) Pramipexole transdermal delivery system and uses thereof
JP2022511673A (ja) 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
TW202430177A (zh) 右旋美索芬之經皮輸送
HK40129313A (en) Transdermal delivery of dextromethorphan
HK40025664A (en) Transdermal drug delivery system for ketamine